FundedIQ
Biotechnology

Inimmune: Funding, Investors & Team (Oct 2026)

Inimmune is focused on the discovery and development of novel immunotherapeutics for an array of disease areas. Inimmune technology is focused on the discovery, optimization, and development of new innate immune receptor agonists and antagonists to treat a wide array of medical conditions including allergy, autoimmune diseases, and cancer. It was founded in 2016 and based in Missoula, Montana.

inimmune.com LinkedIn Missoula, United States 11-50 employees
Total raised
$22.0M
Rounds
1
Latest
Undisclosed round
Jul 2020

Inimmune has raised $22.0M across 1 funding round on record, the most recent an undisclosed round of $22.0M announced in Jul 2020.

That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.

Inimmune Company Profile and Key Stats

Total funding raised
$22.0M
across 1 round on record
Funding rounds on record
1
Latest funding round
Undisclosed round
$22.0M in Jul 2020
Employees
11-50
reported band
Headquarters
Missoula, United States

Latest funding round on record: Jul 2020.

Inimmune Funding Rounds

Date
Round
Amount
Undisclosed round
$22.0M

Inimmune Founders and Leadership Team

Name
Role
Contact
Evans Jay
CEO
Locked

Contact details for the Inimmune team: 1 of 1 has an email address on file.

Start 14-day free trial →

Inimmune Funding Compared to Other Biotechnology Startups

Segment
Companies
Median round
4,185
$8.1M
30,234
$7.6M

Inimmune's latest round of $22.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.

Funded Startups Like Inimmune in Biotechnology and Missoula

Companies Similar to Inimmune

Series B $150M

Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…

Undisclosed round $94.0M

Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…

Series B $9.5M

Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…

Series B $33.0M

Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…

Undisclosed round —

Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.

Series A $15.0M

Serán is a contract development and manufacturing organization providing a comprehensive suite of…

Private Equity —

Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…

Series D $250M

Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…

Series E $311M

Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…

Undisclosed round $8.5M

Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…

Series E $92.5M

Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…

Series B $40.0M

Inimmune Funding FAQs

What does Inimmune do?

Inimmune is focused on the discovery and development of novel immunotherapeutics for an array of disease areas. Inimmune technology is focused on the discovery, optimization, and development of new innate immune receptor agonists and antagonists to treat a wide array of medical conditions including allergy, autoimmune diseases, and cancer. It was founded in 2016 and based in Missoula, Montana.

How much funding has Inimmune raised?

Inimmune has raised $22.0M across 1 round on record. The most recent is an undisclosed round of $22.0M announced in Jul 2020.

When did Inimmune last raise funding?

Inimmune's most recent funding round on record is an undisclosed round of $22.0M, announced in Jul 2020.

Who is the CEO of Inimmune?

Evans Jay is listed as CEO at Inimmune.

Where is Inimmune headquartered?

Inimmune is based in Missoula, Montana, United States.

How many employees does Inimmune have?

Inimmune is in the 11-50 employee band.

How does Inimmune's funding compare to other Biotechnology startups?

Inimmune's latest round of $22.0M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.

About FundedIQ's Inimmune Funding Data

FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.

Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Inimmune is left off this page rather than filled in.

14-day free trial · Cancel anytime

Know who just raised. Then know who to reach.

Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.

Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.